Targeted outreach to women who inject opioids

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29